Why is the Paradigm share price surging 5% today?

What's driving the Paradigm share price higher on Thursday?

| More on:
A woman sits on a doctor's table as he examines her knee for osteoarthritis as part of Paradigm's study

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Paradigm shares zip 4.88% higher to $1.29 apiece
  • The company provided an update on its osteoarthritis study, advising the first subjects have been randomised and dosed 
  • The clinical trial is currently enrolling subjects at eight sites in Australia and 21 in the US 

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is racing higher during early afternoon trade on Thursday.

This comes after the biopharmaceutical company provided an update on its pivotal phase 3 clinical trial.

At the time of writing, the Paradigm share price is $1.29, up 4.88%.

What did Paradigm announce?

In today's statement, Paradigm said the first subjects in the PARA_OA_002 clinical trial have been randomised and dosed in the United States.

The study's objective is to evaluate the treatment of pentosan polysulfate sodium (PPS) on participants with knee osteoarthritis pain.

PPS, an injectable solution, aims to treat musculoskeletal disorders caused by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition.

The semi-synthetic drug is packaged as Zilosul. It has been shown to reduce pain, improve joint function, and prevent cartilage damaging joints.

Paradigm noted that the first subject randomisation occurred at Northwestern University in Chicago. It was conducted by lead investigator Dr Thomas Schnitzer.

The PARA_OA_002 study is currently enrolling subjects at eight sites in Australia and 21 sites in the US. In addition, locations in the United Kingdom and Europe are expected to be initiated in 2022.

Paradigm will evaluate study participants using WOMAC pain and WOMAC function at multiple time points from day 56 to day 168.

WOMAC is a widely-used health tool that assesses physical function, pain, and stiffness in patients with osteoarthritis. The self-administered instrument gives a score range for each of the three subclasses to indicate the patient's health status.

Management commentary

Paradigm chief medical officer and interim CEO Dr Donna Skerrett said:

To have our first subjects randomised in the US is an important milestone in the OA clinical program.

The Paradigm clinical team has been working tirelessly to initiate and activate sites throughout the US and we are seeing a large number of subjects entering the screening phase throughout the US.

We look forward to continuing the strong momentum in the phase 3 program and reporting important recruitment milestones to our shareholders.

Paradigm share price snapshot

From November 2021, the Paradigm share price has been on a trending decline.

Paradigm shares hit an all-time low of 92.5 cents last month and have since moved in a sideways channel.

While falling 44% over the past 12 months, the bulk of these losses have come in 2022 — down 32%.

Based on valuation grounds, Paradigm commands a market capitalisation of roughly $286.19 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »